Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma

por Kovács, Petra Terézia, Mayer, Tamás, Csizmarik, Anita, Váradi, Melinda, Oláh, Csilla, Széles, Ádám, Tschirdewahn, Stephan, Krafft, Ulrich, Hadaschik, Boris, Nyirády, Péter, Riesz, Péter, Szarvas, Tibor
Publicado 2022

Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis

por Széles, Ádám, Fazekas, Tamás, Váncsa, Szilard, Váradi, Melinda, Kovács, Petra Terézia, Krafft, Ulrich, Grünwald, Viktor, Hadaschik, Boris, Csizmarik, Anita, Hegyi, Péter, Váradi, Alex, Nyirády, Péter, Szarvas, Tibor
Publicado 2022

Comprehensive Analysis of the Prognostic Value of Circulating MMP-7 Levels in Urothelial Carcinoma: A Combined Cohort Analysis, Systematic Review, and Meta-Analysis

por Kubik, András, das Virgens, Isabel Pinto Amorim, Szabó, Anett, Váradi, Melinda, Csizmarik, Anita, Keszthelyi, Attila, Majoros, Attila, Fehérvári, Péter, Hegyi, Péter, Ács, Nándor, Nyirády, Péter, Szarvas, Tibor
Publicado 2023

MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients

por Szarvas, Tibor, Hoffmann, Michèle J., Olah, Csilla, Szekely, Eszter, Kiss, Andras, Hess, Jochen, Tschirdewahn, Stephan, Hadaschik, Boris, Grotheer, Vera, Nyirady, Peter, Csizmarik, Anita, Varadi, Melinda, Reis, Henning
Publicado 2020

High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy

por Krafft, Ulrich, Olah, Csilla, Reis, Henning, Kesch, Claudia, Darr, Christopher, Grünwald, Viktor, Tschirdewahn, Stephan, Hadaschik, Boris, Horvath, Orsolya, Kenessey, Istvan, Nyirady, Peter, Varadi, Melinda, Modos, Orsolya, Csizmarik, Anita, Szarvas, Tibor
Publicado 2021

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer

por Olah, Csilla, Reis, Henning, Hoffmann, Michèle J., Mairinger, Fabian, Ting, Saskia, Hadaschik, Boris, Krafft, Ulrich, Grünwald, Viktor, Nyirady, Peter, Varadi, Melinda, Győrffy, Balázs, Kiss, Andras, Szekely, Eszter, Sjödahl, Gottfrid, Szarvas, Tibor
Publicado 2022

Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study

por Váradi, Melinda, Horváth, Orsolya, Módos, Orsolya, Fazekas, Tamás, Grunewald, Camilla M., Niegisch, Günter, Krafft, Ulrich, Grünwald, Viktor, Hadaschik, Boris, Olah, Csilla, Maráz, Anikó, Furka, Andrea, Szűcs, Miklós, Nyirády, Péter, Szarvas, Tibor
Publicado 2023

High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma

por Széles, Ádám, Kovács, Petra Terézia, Csizmarik, Anita, Váradi, Melinda, Riesz, Péter, Fazekas, Tamás, Váncsa, Szilárd, Hegyi, Péter, Oláh, Csilla, Tschirdewahn, Stephan, Darr, Christopher, Krafft, Ulrich, Grünwald, Viktor, Hadaschik, Boris, Horváth, Orsolya, Nyirády, Péter, Szarvas, Tibor
Publicado 2022

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas

por Varadi, Melinda, Nagy, Nikolett, Reis, Henning, Hadaschik, Boris, Niedworok, Christian, Modos, Orsolya, Szendroi, Attila, Ablat, Jason, Black, Peter C., Keresztes, David, Csizmarik, Anita, Olah, Csilla, Gaisa, Nadine T., Kiss, Andras, Timar, Jozsef, Toth, Erika, Csernak, Erzsebet, Gerstner, Arpad, Mittal, Vinay, Karkampouna, Sofia, Kruithof de Julio, Marianna, Gyorffy, Balazs, Bedics, Gabor, Rink, Michael, Fisch, Margit, Nyirady, Peter, Szarvas, Tibor
Publicado 2023